Vicenin‐2 acts as a radiosensitizer of the non‐small cell lung cancer by lowering Akt expression. (29th November 2018)

• Record Type: Journal Article
• Authors: Baruah, Taranga Jyoti; Kma, Lakhon
• Is Part Of: BioFactors. Volume 45:Number 2(2019)
• Page Start: 200
• Page End: 210
• Publication Date: 2018-11-29
• Subjects: Vicenin‐2 -- non‐small cell lung cancer -- radiosensitization -- PTEN -- PI3K -- Akt -- apoptosis; Vitamins -- Physiological effect -- Periodicals; Trace elements -- Physiological effect -- Periodicals; Growth factors -- Physiological effect -- Periodicals; Plant growth promoting substances -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Nutritional Physiological Phenomena -- Periodicals; Trace Elements -- metabolism -- Periodicals; Vitamins -- metabolism -- Periodicals; Molecular Biology -- Periodicals; 612.399
• DOI: 10.1002/biof.1472
• Languages: English
• ISSNs: 0951-6433

Abstract

Abstract: Non‐small cell lung cancer (NSCLC) has a very high rate of incidence and is resistant to chemo‐ and radiotherapy. Vicenin‐2 (VCN‐2) is a flavonoid obtained from Ocimum sanctum L. and it has been reported to have radioprotective, anticancer, and radiosensitizing properties. We have conducted this study to check the effect of VCN‐2 on the cell viability and the effect on PTEN (Phosphatase and tensin homolog), PI3KCA (Phosphatidylinositol 4, 5‐biphosphate 3‐kinase catalytic subunit alpha isoform/PI3K 110α subunit), and Akt1 when VCN‐2 was used alone and in combination with radiation in the NSCLC cell line NCI‐H23 (H23). We have also checked the effect of VCN‐2 on various pro‐ and anti‐apoptotic genes and the ultra‐morphological changes that occurred in the cells when VCN‐2 is used alone and in combination with radiation. VCN‐2 was able to lower cancer cell survival and phosphorylated Akt while promoting the expression of pro‐apoptotic genes and down‐regulating anti‐apoptotic genes. We also observed the apoptosis‐associated ultra‐morphological changes in the VCN‐2‐treated cells. Our study have demonstrated that VCN‐2 can be a potential chemotherapeutic and radiosensitizing agent in NSCLC. © 2018 BioFactors, 45(2):200–210, 2019